The incidences of major or nonmajor clinically relevant bleeding with rivaroxaban were not significantly different from those with enoxaparin/VKA , either with ( 105 of 3,485 , 3.0 % vs. 104 of 3,428 , 3.0 % ; adjusted HR = 0.98 ; 95 % CI = 0.75 to 1.29 ) or without ( 24 of 645 , 3.7 % vs. 30 of 688,4.4 % ; adjusted HR = 0.81 ; 95 % CI = 0.46 to 1.40 ; pinteraction = 0.68 ) prestudy heparin .